In Feb, 2024, Jiudian Hongyang Pharmaceutical, which is wholly-owned subsidiary of Jiudian Pharmaceutical, have market authorization of dapoxetine hydrochloride and celecoxib  Nicorandil API from NMPA.

Dapoxetine hydrochloride is the first-line clinical drug for the treatment of male premature ejaculation.

Celecoxib is the largest non-steroidal anti-inflammatory analgesic prescribed drug in the world, and has been included in the national collection in China.

In 2017, Nicorandil tablets entered the National Medical Insurance Catalogue (Class B), and now it is a national medical insurance (Class A) drug in 2022.

The dosage forms of Nicorandil sold in China include tablets and injections, and injection has already dominate the sales market.

Nicorandil sales in the Chinese market have increased year by year.

These three authorization indicate that Jiudian market will make further progress.